Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | Zendy

Lisa M. Dunkle | Zendy; Karen L. Kotloff | Zendy; Cynthia L. Gay | Zendy; Germán Áñez | Zendy; Jeffrey Adelglass | Zendy; Alejandro Quintín Barrat Hernández | Zendy; Wayne L. Harper | Zendy; Daniel M. Duncanson | Zendy; Monica A. McArthur | Zendy; Diana F. Florescu | Zendy; R. Scott McClelland | Zendy; Veronica Garcia-Fragoso | Zendy; Robert Riesenberg | Zendy; David B. Musante | Zendy; David L. Fried | Zendy; Beth Safirstein | Zendy; Mark McKenzie | Zendy; Robert Jeanfreau | Zendy; Jeffrey K. Kingsley | Zendy; Jeffrey A. Henderson | Zendy; Dakotah C. Lane | Zendy; Guillermo M. RuizPalacios | Zendy; Lawrence Corey | Zendy; Kathleen M. Neuzil | Zendy; Robert W. Coombs | Zendy; Alexander L. Greninger | Zendy; Julia Hütter | Zendy; Julie A. Ake | Zendy; Katherine R. Smith | Zendy; Wayne Woo | Zendy; Iksung Cho | Zendy; Gregory M. Glenn | Zendy; Filip Dubovsky | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Author(s) -

Lisa M. Dunkle,

Karen L. Kotloff,

Cynthia L. Gay,

Germán Áñez,

Jeffrey Adelglass,

Alejandro Quintín Barrat Hernández,

Wayne L. Harper,

Daniel M. Duncanson,

Monica A. McArthur,

Diana F. Florescu,

R. Scott McClelland,

Veronica Garcia-Fragoso,

Robert Riesenberg,

David B. Musante,

David L. Fried,

Beth Safirstein,

Mark McKenzie,

Robert Jeanfreau,

Jeffrey K. Kingsley,

Jeffrey A. Henderson,

Dakotah C. Lane,

Guillermo M. RuizPalacios,

Lawrence Corey,

Kathleen M. Neuzil,

Robert W. Coombs,

Alexander L. Greninger,

Julia Hütter,

Julie A. Ake,

Katherine R. Smith,

Wayne Woo,

Iksung Cho,

Gregory M. Glenn,

Filip Dubovsky

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2116185

Subject(s) - covid-19 , clinical trial , coronavirus , medicine , environmental health , virology , family medicine , disease , infectious disease (medical specialty) , outbreak

NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in North America.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research